Why Metformin Causes Lactic Acidosis
Metformin causes lactic acidosis through toxic drug accumulation when renal clearance is impaired, leading to inhibition of mitochondrial respiration and subsequent lactate overproduction that overwhelms the body's clearance capacity.
Mechanism of Metformin-Associated Lactic Acidosis
Metformin-associated lactic acidosis (MALA) occurs through a specific pathophysiological cascade:
Primary mechanism: Metformin inhibits mitochondrial oxidative phosphorylation (Complex I of the respiratory chain), particularly in the liver 1, 2. This mitochondrial impairment leads to:
- ATP depletion at the cellular level
- Acceleration of glycolytic flux as cells attempt to compensate for reduced oxidative metabolism
- Increased glucose uptake and conversion to lactate
- Lactate efflux into circulation rather than further oxidation 3
The liver is the key organ where both metformin's therapeutic glucose-lowering effect and its potential for causing lactic acidosis converge 3.
Why Accumulation Occurs
Metformin is renally excreted and not metabolized 4, 5, 6. The drug's clearance is directly proportional to GFR 5. According to FDA labeling, metformin decreases liver uptake of lactate, increasing blood lactate levels in a plasma concentration-dependent manner 6.
When renal function declines:
- Metformin clearance decreases by approximately 75% when GFR drops to 60 mL/min/1.73 m² 4
- Drug accumulation leads to plasma metformin levels >5 mcg/mL (the threshold associated with MALA) 6
- Elevated metformin concentrations directly correlate with increased lactate production 2
The "Two-Hit" Requirement
MALA typically requires two conditions to occur simultaneously 2:
- Elevated plasma metformin concentrations (from renal impairment or overdose)
- A secondary event that further disrupts lactate metabolism, such as:
Clinical Characteristics
When MALA develops, it presents with 6, 1:
- Blood lactate >5 mmol/L
- High anion gap metabolic acidosis (without ketonuria/ketonemia)
- Increased lactate:pyruvate ratio
- Metformin plasma levels generally >5 mcg/mL
Important caveat: The actual incidence of MALA is extremely rare (<10 cases per 100,000 patient-years) 2. A Cochrane meta-analysis found no cases of lactic acidosis in 37,360 metformin patient-years 5. This suggests that metformin alone, at therapeutic doses with normal renal function, does not cause lactic acidosis—the secondary precipitating factors are critical 3.
Risk Stratification by Renal Function
Per FDA labeling and guidelines 6:
- eGFR <30 mL/min/1.73 m²: Contraindicated (metformin cannot be cleared adequately)
- eGFR 30-45 mL/min/1.73 m²: Initiation not recommended; if already on therapy, assess benefit vs. risk
- eGFR 45-60 mL/min/1.73 m²: Use with caution, dose reduction recommended 5
- eGFR ≥60 mL/min/1.73 m²: Safe to use
Why Hepatic Impairment Matters
Liver disease is a critical but underappreciated risk factor 3. The liver is responsible for lactate clearance through gluconeogenesis. When hepatic function is impaired:
- Lactate clearance is reduced regardless of metformin levels
- Combined with metformin's inhibition of hepatic lactate uptake, this creates a "perfect storm" for lactate accumulation
- Renal dysfunction alone may only be dangerous when associated with liver failure 3
Alcohol's Unique Role
Excessive alcohol consumption independently increases MALA risk 8. Ethanol oxidation consumes NAD+ (nicotinamide adenine dinucleotides), which are also required for lactate metabolism. This creates competition for the same cofactor needed to clear lactate, making patients vulnerable to MALA even with normal baseline renal function 8.